T he use of antiplatelet medications such as lowdose aspirin and/or the thienopyridines (eg, clopidogrel) significantly decreases major cardiovascular events. 1 However, gastrointestinal bleeding (GIB) is a serious adverse event in patients taking antiplatelet medications. Randomized controlled trials of low-dose aspirin for cardiovascular prophylaxis indicate approximately 2-fold increase in GIB with low-dose aspirin, whereas the addition of clopidogrel increases GIB risk by approximately another 2-fold as compared with aspirin monotherapy. [2] [3] [4] [5] Aspirin and the thienopyridines clopidogrel and prasugrel irreversibly block platelet function for the life span of the platelet, approximately 8-10 days. For this reason the antiplatelet effect of these medications lasts for days after ingestion of the last dose. Current guidelines and expert opinion indicate that platelet transfusion is a treatment option in patients on antiplatelet agents with serious GIB, even in the face of normal platelet counts. 6, 7 Theoretically, this would provide functional platelets to help stop active bleeding and to prevent rebleeding. However, a major concern is that the rapid provision of functional platelets could have significant cardiovascular side effects, principally arterial thrombotic events such as stent thrombosis, myocardial infarction, or stroke. No studies assessing platelet transfusions in patients with acute GIB, whether or not on antiplatelet agents, were identified by a recent systematic review. 8 We know of a single abstract, published after the aforementioned systematic review, that retrospectively assessed 35 patients with non-variceal GIB while on antiplatelet agents and 48 unmatched controls with nonvariceal GIB not on antiplatelet medications. 9 This small study, which examined only clinical benefit related to GIB and did not adjust for potential confounding characteristics, reported no clinical benefit with platelet transfusion.
Because of the lack of information on the potential benefits or harms with platelet transfusion in patients with acute GIB while on antiplatelet agents, we performed a retrospective cohort study that matched cases with controls and adjusted for potential confounding characteristics to assess whether platelet transfusions would decrease rebleeding in patients on antiplatelet agents or increase the number of major adverse cardiovascular events (MACE).
Methods

Subject Selection
By using International Classification of Diseases, 9th Revision codes (Supplementary Table 1 ), the patient database at Yale-New Haven Hospital (York Street Campus from 2008 to 2013 and Chapel Street Campus from its merger with Yale-New Haven Hospital in June 2013 to December 2013) was interrogated to find all patients admitted through the emergency department with GIB. GIB that developed in patients already hospitalized was excluded. Patients with GIB were separated into those who did and did not receive platelet transfusion by using blood bank charge codes for platelets (Supplementary Table 2) .
Charts of patients receiving platelet transfusion were reviewed to identify eligible subjects for our case cohort. Inclusion criteria were age >18 years, platelet count >100 Â 10 9 /L, and use of antiplatelet medication. Pregnant patients were excluded. Patients were only recorded once; if a patient had recurrent GIB after discharge from the index bleeding episode, only the index GIB episode was included.
Once our case cohort was finalized, we reviewed the charts of GIB patients without platelet transfusion to identify matched subjects to act as a control cohort. Controls were matched to cases (1:1 ratio) for sex and age. They were also matched for GIB location (upper vs colonic/small intestinal) if the appropriate control was present. Consecutive sampling was performed to create the matched cohort. Inclusion criteria for control subjects were platelet counts >100 Â 10 9 /L and use of antiplatelet medications. Exclusion criteria for controls were pregnancy and any contraindication to platelet transfusion (eg, left ventricular assist device, thrombotic or idiopathic thrombocytopenic purpura, heparin-induced thrombocytopenia, transfusion reaction history, or patient declining treatment). Decisions regarding transfusion of platelets were made at the discretion of the patient's physicians; no specific guidelines were in place that dictated use of platelet transfusions.
Data Collection
Baseline demographic and clinical information was recorded on chart review, and Charlson comorbidity index 10 was calculated. Information collected on the GIB episode included location, endoscopic findings, endoscopic interventions, interventional radiologic or surgical interventions, and transfusion of blood products. Upper GIB from ulcers was divided into low-risk (clean base or flat spot) and high-risk (adherent clot, visible vessel, or active bleeding). The primary outcome measure was recurrent GIB during the hospital admission, which was defined as new hematemesis, new hematochezia after normalization of stool or after melena, new melena after normalization of stool, chart documentation by clinician of recurrent GIB, or documentation of recurrent GIB at endoscopy, interventional radiology, or surgery.
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Additional predefined end points during the hospital admission included MACE (defined as myocardial infarction, stroke, arterial thromboembolic event, or cardiovascular death), myocardial infarction (documented by elevated troponin during admission), mortality, length of hospital stay, and red cell transfusion. For patients who died during hospitalization, 2 authors (L.Z., M.D.) independently reviewed the medical records to determine cause of death. GIB-related death was defined as death due to persistent GIB or to recurrent GIB or to complications of interventions to treat GIB. Any disagreement was resolved by discussion and consensus; if disagreement was not resolved, the senior author (L.L.) was to act as final arbiter.
The study was approved by the Yale University Human Research Protection Program.
Data Analysis
Student t test was used to compare continuous measures, and Fisher exact test was used for comparison of categorical variables. Multivariable logistic regression analyses were performed to adjust for potentially confounding characteristics. We planned to include variables potentially related to severity of bleeding or cardiovascular risk, with P .10 on univariate analysis. We also planned on sensitivity analyses including all characteristics that showed P .10 on univariate analysis and including only characteristics related to severity of bleeding, with P .10 on univariate analysis. We planned on assessing the outcome of red cell transfusions but realized this is both an indicator of initial severity of GIB and an outcome measure. Therefore, we also planned a sensitivity analysis that included the independent variable of red cell transfusion in the first 24 hours after presentation along with the baseline characteristics, with P .10 on univariate analysis. Analyses were performed with JMP 10.0.0 software (SAS Institute, Inc, Cary, NC).
Sample size calculation demonstrated that a sample size of 199 in each group is required for rebleeding rate of 20% in the controls and 10% in the cases, with alpha of 0.05 and power of 80%. We used an estimate of 20% on the basis of a large observational study indicating 17% incidence of recurrent bleeding in patients with upper GIB who take nonsteroidal anti-inflammatory drugs and in patients with upper GIB who take anticoagulants. Although no prior study provides information about an expected decrease in recurrent GIB with platelet transfusion, we chose 50% relative risk reduction as a clinically meaningful reduction. 12 
Results
Our case cohort consisted of 204 patients admitted with GIB while on antiplatelet agents who received platelet transfusion. The control cohort consisted of 204 matched patients. Baseline characteristics and medication usage are shown in Tables 1 and 2 . Almost all patients were on aspirin, with about 30% on dual antiplatelet therapy (aspirin and clopidogrel) ( Table 2) . Aspirin was resumed by the time of discharge in 57 of 190 cases (30%) and 76 of 201 controls (38%) who survived to discharge (P ¼ .11). Both groups had similar platelet counts (case average, 260 Â 10 9 /L vs control average, 259 Â 10 9 /L). Case patients appeared to have more severe GIB than control patients, with higher proportions having admission heart rate >100 beats per minute, mean arterial pressure <65 mm Hg, initial hemoglobin <7 g/dL, and admission to intensive care (Table 1) . Comorbidities, including cardiovascular disease and coronary artery stents, were not higher in the cases than in the controls (Table 1) . Finally, there was a slightly higher usage of proton pump inhibitors before GIB in control patients. The types of GIB episodes were similar in the cases and controls (Table 3) .
Univariate analysis showed significantly greater rates of rebleeding, MACE, myocardial infarction, mortality, and prolonged length of stay with platelet transfusion as compared with no platelet transfusion (Table 4) . It should be noted that all but 1 patient meeting criteria for an MACE event also met criteria for myocardial infarction. We also found that the time to MACE was short, with 37 of 46 myocardial infarctions (80%) in cases and 23 of 26 myocardial infarctions (88%) in controls occurring within 48 hours of admission (Supplementary Figure 1) . Furthermore, the primary multivariable analysis, adjusting for admission tachycardia, admission hypotension, intensive care unit admission, admission hemoglobin <7 g/dL, and previous coronary artery stenting revealed a significant difference only in mortality (adjusted odds ratio [OR], 5.57; 95% confidence interval, 1.52-27.1). Sensitivity analyses incorporating all characteristics with P .10 on univariate analysis and incorporating only such characteristics that related to GIB severity showed similar results, with significant differences only for mortality (adjusted ORs, 6.76; 1.74-34.4 and 5.31; 1.47-25.5, respectively).
Four of the 14 deaths in those who received platelets and 1 of the 3 deaths in those who did not receive platelets were due to cardiovascular causes. However, 10 of the deaths in the cases were due to GIB, whereas no deaths in the control group were attributed to GIB. Figure 1 shows the time to death after admission among Cases and controls had similar rates of endoscopy, endoscopic intervention, and types of endoscopic intervention (Table 5 ). Furthermore, cases and controls had similar times to endoscopic interventions, with 40 of 49 cases (82%) and 28 of 40 controls (70%) receiving intervention within 24 hours (P ¼ .22). Cases were more likely to undergo interventional radiology or surgical procedures (Table 5) , which was potentially related to increased severity of the bleeding episode and/or platelet transfusions ordered in anticipation of an intervention.
Post hoc sensitivity analyses restricted to patients with non-variceal upper GIB (N ¼ 117 cases, 115 controls) and to patients with colonic GIB (N ¼ 80 cases, 81 controls) were also performed (Supplementary Tables 3  and 4 ). The sample sizes were smaller in these sensitivity analyses, and the increase in mortality was not significant in either analysis. The adjusted OR for mortality was numerically higher in colonic GIB than in non-variceal upper GIB, but the confidence intervals were broad and widely overlapping, 4.13 (0.41-96.4) and 1.65 (0.31-13.3), respectively.
Discussion
Our results indicate that platelet transfusion for patients with GIB on antiplatelet medications does not improve clinical outcomes. In fact, mortality was markedly higher in patients receiving platelet transfusion than in those not receiving platelets, even after adjusting for a number of potentially confounding characteristics. We acknowledge that this difference in mortality could be due to residual bias from unmeasured and unknown factors and reflect the increased severity of GIB in patients receiving platelet transfusion. On the other hand, the adjusted ORs for mortality (4.5-6.8 with different sensitivity analyses) are large, increasing the likelihood of a cause-and-effect relationship.
Although the reliability of physicians' assessment of the cause of death as GIB, cardiovascular, or other etiologies is uncertain, much of the difference in mortality with platelet transfusion in our study was driven by deaths considered related to GIB rather than cardiovascular disease. This finding differs from most other studies of GIB, which show that a majority of patients with GIB who die during hospitalization or within 30 days after the index GIB episode die of non-GIB-related causes. 13 Furthermore, studies that follow patients who developed GIB while on antiplatelet medications demonstrate that deaths during a period of 1-12 months after the GIB episode also are primarily due to non-GIBrelated causes. [14] [15] [16] [17] The reason a higher proportion of patients in our study than in prior studies died as a result of GIB is uncertain, but 3 possibilities may be considered. First, patients who received platelet transfusions appeared to represent a subset of GIB patients who have more severe bleeding and thus may have higher mortality as a result of GIB than the overall group of patients taking antiplatelet agents who present with GIB. Second, patients taking antiplatelet agents might have been more likely to have persistent or recurrent bleeding during hospitalization because of the long-lasting antiplatelet effects of agents such as aspirin and thienopyridines. Third, platelet transfusions might increase the risk of severe and fatal GIB.
Mechanisms by which platelet transfusion would increase mortality or GIB-related mortality are not clear. The use of aspirin or non-aspirin antiplatelet medication in patients presenting with upper GIB is reported to be associated with improved outcomes such as mortality and rebleeding in prospective 15 and retrospective studies. 18 One may speculate that such benefits with antiplatelet agents could be reduced with the rapid infusion of functional platelets. In addition to their effect on thrombosis, platelet transfusions are reported to be proinflammatory and alter recipient immunity. 19 Transfusion of blood products has been documented to worsen outcomes. A liberal red cell transfusion strategy increased mortality, further GIB, and fatal GIB in a randomized trial. 20 Whether this was related to increased volume in the splanchnic circulation or other effects of blood products is uncertain. Platelet transfusions have also been reported to increase bleeding and mortality in other settings. A retrospective analysis of data collected in double-blind placebo-controlled trials of patients undergoing coronary artery bypass graft surgery showed more bleeding and higher mortality in patients receiving platelet transfusions than in those not receiving platelets. 21 Subsequent analysis by using propensity scoring revealed the OR for death with platelet transfusion to be 4.76 (1.65-13.73) . Although more research is necessary to assess potential harmful effects of platelet transfusions and understand potential Adjusted for coronary artery stent, mean arterial pressure <65 mm Hg, heart rate >100 bpm, initial intensive care unit admission, and initial hemoglobin <7 g/dL. Figure  1 . Time after admission to death in the case and control cohorts.
mechanisms, the observation of increased mortality without documentation of clinical benefit suggests a very cautious approach to the use of platelet transfusion.
Although current guidelines from the American Society for Gastrointestinal Endoscopy indicate platelet transfusion is an option in patients on antiplatelet agents with serious GIB, no evidence is presented to support this practice. 6 Current guidelines from the AABB (formerly the American Association of Blood Banks) state they cannot recommend for or against platelet transfusion for patients receiving antiplatelet therapy who have intracranial hemorrhage, a much more serious condition than GIB, because of heterogeneous results without overall clinical benefit shown in the available small observational studies. 22 We believe the most prudent way to manage patients on antiplatelet agents with GIB is to follow current evidence-based recommendations for all patients with GIB, eg, early endoscopy ( 12-24 hours after presentation), endoscopic hemostatic therapy for high-risk lesions, and intensive proton pump inhibitor therapy in patients with ulcers and highrisk endoscopic features. 23 In addition, although not based on high-quality evidence, we believe that hemostatic techniques that do not cause significant tissue damage (eg, clips rather than thermal devices or sclerosants) should be used in patients on antiplatelet agents, especially if patients are expected to remain on these agents in the future. 24 The major limitation of our study is its retrospective nature. Our sample size was large enough to detect clinically relevant absolute differences of 10% in rates of rebleeding and cardiovascular events. Furthermore, we were able to collect data on most known potential confounding characteristics of each patient through extensive medical chart review. Nevertheless, statistical analysis may not be able to fully adjust for differences in cohort studies, and residual bias due to differences in bleeding severity between cases and controls may account for at least a portion of our findings. Our results apply to individuals developing GIB as an outpatient and may not be generalizable to patients who develop GIB while hospitalized for another condition. Inpatients who develop GIB are older, sicker, and more likely to use nonaspirin antithrombotic agents than outpatients who develop GIB. 25 Our study population was also heterogeneous, including GIB from a variety of sources throughout the upper and lower gastrointestinal tract. Whether platelet transfusion has differing effects on different sources of GIB is unknown. The fact that sources of GIB were wellmatched in our study should help mitigate this issue. Furthermore, because only 1% of patients had bleeding that was due to varices, the results may not be generalizable to patients with variceal bleeding.
In summary, platelet transfusion in patients with GIB on antiplatelet agents without thrombocytopenia did not reduce rebleeding but was associated with greater mortality. Because of the lack of benefit, our results do not support the use of platelet transfusion in patients with GIB who are taking antiplatelet agents. Further study should be performed to enhance the extremely limited body of evidence regarding platelet transfusion in patients taking antiplatelet agents and better assess this practice in patients with GIB. Practices that are based on conjecture may not benefit our patients, while increasing cost and potentially even causing harm. 
